Thermo Fisher Scientific (TMO) Financial History

In December 2021, the Organization for Economic Cooperation and Development (“OECD”) published a proposal for the establishment of a global minimum tax rate of 15% (the “Pillar Two rule”).

Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties.

The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development services, are subject to extensive ongoing regulation by the FDA, th…

New governmental regulations or changes in existing governmental regulations may reduce demand for our products or increase our expenses.

Our success is largely dependent upon our ability to attract and retain a highly qualified workforce, comprised of scientific, technical, clinical, and management talent.

become increasingly sophisticated and more difficult to predict and protect against, particularly with the advancement of AI.

Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and inefficiencies.

Moreover, we have acquired many companies and businesses.

•finding new markets for our products and services; and

Many of our existing products and services and those under development are technologically innovative and require significant planning, design, development and testing at the technological, safety, quality, product an…

We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products and services by competitors and maintain quality to remain competitive.

Demand for some of our products depends on capital spending policies of our customers and on government funding policies.

•diverse data privacy, protection and localization requirements;

•the impact of public health emergencies, pandemics, epidemics or other health outbreaks on the global economy;

•interruption to transportation flows for delivery of raw materials or parts to us and finished goods to our customers;

In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the U.S.

Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.

•reducing demand for some of our products and services;

In December 2021, the Organization for Economic Cooperation and Development (“OECD”) published a proposal for the establishment of a global minimum tax rate of 15% (the “Pillar Two rule”).

Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business partners or other third parties.

laboratory-developed tests could delay and add to the cost of commercialization of these products, as well as subject us to additional regulatory controls.

•tariffs imposed by the U.S.

from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients or personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could…

We and our third-party providers experience cyber-attacks and other attempts to gain unauthorized access to our products, services, and systems and data on a regular basis, and we anticipate continuing to be subject t…

•Chinese regulations requiring the use of local suppliers, which compel companies that do business in China to partner with local companies to conduct business and provide incentives to government-backed local custome…

•tariffs imposed by the U.S.